---
document_datetime: 2025-10-02 11:37:12
document_pages: 44
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xtandi-h-c-002639-x-0029-epar-assessment-report-variation_en.pdf
document_name: xtandi-h-c-002639-x-0029-epar-assessment-report-variation_en.pdf
version: success
processing_time: 104.1605938
conversion_datetime: 2025-12-25 00:23:30.243955
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20July2017 EMA/CHMP/432249/2017 Committee for Medicinal Products for Human Use(CHMP)

## CHMP assessment report on extension(s) of marketing authorisation

## Xtandi

## International non-proprietary name: enzalutamide

## ProcedureNo.EMEA/H/C/002639/X/0029

30ChurchillPlaceCanaryWharfLondonEi45EUUnitedKingdom

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinalproduct:                   | Xtandi                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MAH:                                            | AstellasPharmaEuropeB.V. Sylviusweg 62 2333 BE Leiden NETHERLANDS                                                                                                                                                                                                                                                                                                                             |
| Active substance:                               | ENZALUTAMIDE                                                                                                                                                                                                                                                                                                                                                                                  |
| International Non-proprietary Name/Common Name: | enzalutamide                                                                                                                                                                                                                                                                                                                                                                                  |
| Pharmaco-therapeutic group (ATC Code):          | hormone antagonists andrelated agents, anti-androgens (L02BB04)                                                                                                                                                                                                                                                                                                                               |
| Therapeutic indication(s):                      | Xtandi is indicated for: the treatment of adult men with metastaticcastration-resistantprostate cancerwhoareasymptomaticormildly symptomatic after failure of androgen deprivation therapy inwhom chemotherapy is notyet clinically indicated (see section 5.1) thetreatmentofadultmenwith metastaticcastrationresistantprostate cancerwhose diseasehasprogressedonor afterdocetaxel therapy. |
| Pharmaceuticalforms:                            | Capsule, soft; Film-coated tablet                                                                                                                                                                                                                                                                                                                                                             |
| Strengths:                                      | 40 mgand80 mg                                                                                                                                                                                                                                                                                                                                                                                 |
| Routeofadministration:                          | Oral use                                                                                                                                                                                                                                                                                                                                                                                      |
| Packaging:                                      | blister(PVC/PCTFE/alu)                                                                                                                                                                                                                                                                                                                                                                        |
| Package sizes:                                  | 112 capsules, 112 tablets and56 tablets                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure.                               |                            |
|---------------------------------------------------------------------------|----------------------------|
| 1.1.Submission of the dossier ..                                          |                            |
| 1.2. Steps taken for the assessment of the product                        | 8                          |
| 2. Scientific discussion.                                                 |                            |
| 2.1.Problem statement..                                                   |                            |
| 2.2. Quality aspects                                                      | .10                        |
| 2.2.1.Introduction.                                                       | .10                        |
| 2.2.2.Active Substance..                                                  | . 11                       |
| 2.2.3.Finished MedicinalProduct...                                        | . 11                       |
| Description of theproduct and Pharmaceutical development                  | 11                         |
| Manufacture of the product and process controls ....                      | ..14                       |
| Productspecification...                                                   | .16                        |
| Stabilityoftheproduct.                                                    | 17                         |
| Adventitiousagents....                                                    | ..18                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.     | .18                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects | .18                        |
| 2.2.6. Recommendations for future quality development....                 | ...18                      |
| 2.3. Non-clinical aspects..                                               | .18                        |
| 2.3.1. Ecotoxicity/environmental risk assessment.                         | .18                        |
| 2.3.2.Discussion on non-clinical aspects...                               | .18                        |
| 2.3.3. Conclusion on the non-clinical aspects                             | .18                        |
| 2.4. Clinical aspects ....                                                | .19                        |
| 2.4.1. Introduction...                                                    | ..19                       |
| 2.4.2.Pharmacokinetics                                                    | .19                        |
| 2.4.3. Pharmacodynamics...                                                | .32                        |
| 2.4.4. Discussion on clinical pharmacology.                               | .32                        |
| 2.4.5. Conclusions on clinical pharmacology..                             | .33                        |
| 2.5. Clinical efficacy ....                                               | Error!Bookmarknotdefined.  |
| 2.6. Clinical safety .....                                                | ..33                       |
| 2.6.1.Discussion on clinical safety                                       | 34                         |
| 2.6.2. Conclusions on the clinical safety .                               | ...34                      |
| 2.6.3. PSUR cycle ...                                                     | Error!Bookmark notdefined. |
| 2.7. Risk Management Plan..                                               | .35                        |
| 2.8. Pharmacovigilance .....                                              | .41                        |
| 2.9.Productinformation....                                                | 42                         |
| 2.9.1.User consultation.                                                  | 42                         |
| 3. Benefit-Risk Balance                                                   | 42                         |
| 3.1.Therapeutic Context..                                                 | 42                         |
| 3.2. Favourable effects....                                               | 42                         |
| 3.3.Uncertainties and limitations about favourable effects.               | 43                         |

<div style=\"page-break-after: always\"></div>

3.4.Unfavourableeffects..

3.5.Uncertaintiesandlimitationsaboutunfavourableeffects.

3.6.Effects Table....

3.7.Benefit-riskassessmentanddiscussion.

3.7.1. Importance of favourable and unfavourable effects..

3.7.2. Balance of benefits and risks ..

3.8. Conclusions..

4. Recommendations..

43

.43

.43

43

43

43

43

43

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverseevent

ALP

AlkalinePhosphatase

ALT

Alanineaminotransferase

ANOVA

Analysisofvariance

AR

Androgenreceptor

AST

Aspartateaminotransferase

AUC

Areaundertheconcentration-timecurve

AUCo-72h

Areaundertheconcentration-timecurvefrom timepoint0to timepoint72

hours

AUCinf

Areaundertheconcentration-timecurvefromthetimeofdosingextrapolatedtotimeinfinity

AUClast

Area underthe concentration-time curve from the time of dosing to the last measurable

concentration

AUCtau

Areaunder the concentration-time curve during one 24-hour dosing interval atsteadystate Biopharmaceutics ClassificationSystem

BCS

BMI

Body mass index

CK

Creatinekinase

CL/F

Apparenttotalbodyclearanceafterextravasculardosing

Cmax

Maximum concentration(observed)

Cmin

Minimum(trough)concentration

CQA

Criticalqualityattribute

CTCAE

CommonTerminologyCriteriaforAdverseEvent

CYP

CytochromeP450

DBP

Diastolicbloodpressure

DoE

Designofexperiments

EC

EuropeanCommission

ECG

Electrocardiogram

ESV

End-of-studyvisit

FMEA

Failuremodeeffectsanalysis

GCP

Good Clinical Practice

GGT

Gammaglutamyltransferase

GMR

Geometricleastsquaresmeanratio

HDPE

HighDensityPolyethylene

HPLC

Highperformanceliquidchromatography

HPMCAS

Hypromelloseacetatesuccinate

ICH

InternationalConferenceonHarmonisationofTechnicalRequirementsfor

RegistrationofPharmaceuticalsforHumanUse

IEC

IndependentEthicsCommittee

KF

Karl Fischertitration

入z

Terminaleliminationrateconstant

LLOQ

Lowerlimitofquantitation

M1

EnzalutamideMetabolite1(MDPCoo01)

M2

Enzalutamide Metabolite 2(MDPC0002)

MPR

Metabolite-to-parentratio

MPR (MWC)

MPR corrected for the difference in molecular weight

N/A

Notapplicable

NCI

NationalCancerInstitute

NF

National Formulary

NIRS

Near infrared spectroscopy

PCTFE

Polychlorotrifluoroethylene

PE

Polyethylene

PK

Pharmacokinetics

PKAS

Pharmacokineticanalysisset

Ph. Eur.

European Pharmacopoeia

<div style=\"page-break-after: always\"></div>

| PVC     | Polyvinyl chloride                           |
|---------|----------------------------------------------|
| QC      | Quality Control                              |
| QTcF    | CorrectedQTintervalusingFridericia'sformula  |
| QTPP RH | Qualitytargetproductprofile RelativeHumidity |
| SAE     | Seriousadverseevent                          |
| SAF     | Safety analysis set                          |
| SAP     | Statisticalanalysisplan                      |
| SBP     | Systolicbloodpressure                        |
| SDD     | Spray-dried dispersion                       |
| SmPC    | Summary of Product Characteristics           |
| TAMC    | TotalAerobicMicrobialCount                   |
| TBL     | Total bilirubin                              |
| TEAE    | Treatment-emergentadverseevent               |
| t/2     | Terminaleliminationhalf-life                 |
| tmax    | Timetoattainmaximumconcentration             |
| TYMC    | TotalCombinedYeasts/MouldsCount              |
| UV      | Ultraviolet                                  |
| XRPD    | X-raypowderdiffraction                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1.Submissionofthedossier

film-coatedtablets.

The MAH applied for the following indicationfor the new pharmaceutical form associated with the two new strengths:

- ·t thetreatmentofadultmenwithmetastaticcastration-resistantprostatecancerwhoare is not yet clinically indicated (see section 5.1);
- thetreatmentofadultmenwithmetastaticcastrationresistantprostatecancerwhosediseasehas progressed on or after docetaxel therapy.

Furthermore, the PI is brought in line with the latest QRD template version 10.

## The legal basis for this application refers to:

point(s) (c) (d) - Extensions of marketing authorisations

## InformationonPaediatricrequirements

CW/1/2011on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant toArticle 8 of Regulation(EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## ScientificAdvice

The MAH received Scientific Advice from the CHMP on 27 July 2014 and on 24 September 2015. The Scientific Advicepertained toquality and clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2.Stepstakenfortheassessmentoftheproduct

The Rapporteur appointed by the CHMP was:

Rapporteur: Jorge Camarero Jimenez

- ·The application was received by the EMA on 7 March 2016.
- Theprocedurestartedon24March2016.
- TheRapporteur'sfirstAssessmentReportwascirculatedtoallCHMPmemberson13June2016.The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 21 June 2016.
- During the meeting on 8 July 2016, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP.
- During the meeting on 21 July 2016, the CHMP agreed on the consolidated List of Questions to be sent to the MAH.
- The MAH submitted the responses to the CHMP consolidated List of Questions on 16 May 2017.
- The following GMP inspection(s) were requested by the CHMP and their outcome taken into considerationaspartoftheQuality/Safety/Efficacyassessmentoftheproduct:
- A GMP inspection at 3 sites responsible for manufacturing and testing of the finished product in the wasissuedon28March2017.
- The Rapporteurs circulated the Joint Assessment Report on theresponses to the List of Questions to all CHMPmemberson23June2017.
- During the PRAC meeting on 6 July 2017, the PRAC agreed on the PRAC Assessment Overview and AdvicetoCHMP.
- During the meeting on 20 July 2017, the CHMP, in the light of the overall data submitted and the scientificdiscussionwithintheCommittee,issuedapositiveopinionforanextension(s)ofthemarketing authorisationforXtandion20July2017.

<div style=\"page-break-after: always\"></div>

## 2.Scientific discussion

## 2.1.Problem statement

## Aboutthedisease

The application concerns enzalutamide which isindicated for the treatment of patients with metastatic castration-resistantprostatecancer(mCRPC).

time(e.g.,firstgenerationantiandrogenssuchasflutamideorbicalutamide).

promotediseaseprogression.Themediansurvival ofpatientswithcastration-resistantdiseaseis approximately 1-2 years (Lassi, 2010, Petrylak, 2004).

EU Clinical practiceguidelines(ESMO Guidelines)recommend:abiraterone orenzalutamidefor chemotherapy-naivemetastaticCRPC.Ofnotethemarketingauthorisationofsipuleucel-Twaswithdrawnby line (post docetaxel), cabazitaxel, abiraterone and enzalutamide are recommended (ESMo Guidelines).

## Abouttheproduct

inhibitsnucleartranslocationofactivatedreceptorsandinhibitstheassociationoftheactivatedandrogen resistanttoantiandrogens.Enzalutamidetreatmentdecreasesthegrowthofprostatecancercellsandcan agonistactivity(seeSmPCsection5.1).

EnzalutamidewasapprovedintheEuropeanUnion(EU)on21June20i3forthetreatmentofpatientswith metastatic CRPC patients who had received docetaxel therapy.Approval was subsequently granted in the EU on28November2014fortheuseofenzalutamideinadultmenwithmetastaticCRPCwhoareasymptomatic clinicallyindicated.Enzalutamidehasbeen approvedin more than56 countries.

The approved enzalutamide drugproduct is animmediate-release softgelatin capsule containing 40mg of enzalutamide. The recommended dose is 160 mg of enzalutamide (4 x 40 mg capsules) administered orally

<div style=\"page-break-after: always\"></div>

intolerablesideeffectsoccur.

administrationandadherence.Toaddresstheneedsofthispatientpopulation,analternativeimmediatereleasedosageformofenzalutamidewaspursued.

The application isbased on theresults of a pivotal clinical study to demonstratebioequivalencebetween enzalutamidecapsulesand tabletsforsingle-doseAUCunderfastedandfedconditions(Study9785-CL0014), simulations of steady-state concentration-time profiles(derived from nonparametricsuperposition) in

Scientific Advice was received from the CHMP on the bioequivalence strategy between enzalutamide tablet andcapsuleformulations(EMA/CHMP/SAWP/430462/2014),andonCMCaspects(dissolutiontestmethods) ofthetabletdevelopmentprogram(EMA/CHMP/SAWP/589626/2015).

## Inspection

compliance was issued for the concerned site.Uponrequest,theMAHprovideda riskassessmentwith the aimofassessingtheimpactofthedeficienciesthatwereidentifiedduringtheinspectionandtosupportthe validity of the data on themanufacture and testing of Enzalutamide spray-dried dispersion(SDD) and related tabletDrugProductwithregardtoquality,safetyandefficacy.Inaddition,anotherinspectionatthesitewas performedandaGMPcertificatewasissuedon27thApril2017.

## 2.2.Quality aspects

## 2.2.1.Introduction

substance.

Other ingredients are:

Tablet core: hypromellose acetate succinate, microcrystalline cellulose, colloidal anhydrous silica, croscarmellosesodiumandmagnesiumstearate.

Tablet coating: hypromellose, talc, macrogol (8000), titanium dioxide (E171) and iron oxide yellow (E172).

section6.5oftheSmPC.

<div style=\"page-break-after: always\"></div>

## 2.2.2. Active Substance

Xtandi40and80mgfilm-coatedtabletscontainthesameactivesubstance,enzalutamide,asthatusedto manufacture the already-authorised soft capsules. The active substance is sourced from the same manufacturer, manufactured with the same process and released in accordancewith the same active substance specifications.Therefore, the applicant presented no new information in the active substance part of thedossier(3.2.s) tosupport thislineextension application.

## 2.2.3. Finished Medicinal Product

## DescriptionoftheproductandPharmaceuticaldevelopment

Xtandifilm-coatedtabletscontaineither40or80mgofenzalutamideasactivesubstance.Thecomposition of the tablets is shown in table 1, the two strengths being qualitatively and quantitatively proportional in termsofcomposition.

Table 1: composition of Xtandi film-coated tablets

| Component                        | Function                       | Reference to Quality Standard   | Target Amount per 80 mg Tablet (mg)   | Target Amount per 40 mg Tablet (mg)   |
|----------------------------------|--------------------------------|---------------------------------|---------------------------------------|---------------------------------------|
| Enzalutamide a                   | Active Ingredient              | In-house                        | 800                                   | 40°                                   |
| Hypromellose Acetate Succinate a | Diluent                        | NF                              | 4.2 1st ind                           |                                       |
| Acetonea, c                      | Processing Agent               | Ph.Eur.                         |                                       |                                       |
| Cellulose, Microcrystalline      | Filler                         | Ph.Eur.                         |                                       |                                       |
| Silica, Colloidal Anhydrous      | Glidant                        | Ph.Eur.                         |                                       |                                       |
| Croscarmellose Sodium            | Disintegrant                   | Ph.Eur.                         |                                       |                                       |
| MagnesiumStearate                | Lubricant                      | Ph.Eur.                         |                                       |                                       |
| Core Tablet Weight               | Core Tablet Weight             | Core Tablet Weight              |                                       |                                       |
| OPADRYYellow 03F42210            | Non-fumctional Color Film Coat | In-house                        |                                       |                                       |
| Purified Water                   | Processing Agent               | Ph.Eur.                         |                                       |                                       |
| Total Tablet                     | Total Tablet                   | Total Tablet                    |                                       |                                       |

4.2 1st ind

NA, not applicable; NF,National Formulary; Ph.Eur.,European Pharmacopoeia; SDD, spray-dried dispersion

Thecompositionofthefilm-coatingisshownintable2.

<div style=\"page-break-after: always\"></div>

Table 2: composition of the film-coating

<!-- image -->

| Component        | Reference to Quality Standarrd   | Quantity (M/M %)   | Theoretical Amountper80mg Tablet (mg)   | Theoretical Amount per 40 mg Tablet (mg)“   |
|------------------|----------------------------------|--------------------|-----------------------------------------|---------------------------------------------|
| Hypromellose     | Ph. Eur.                         | 4.2 1st ind        |                                         |                                             |
| Talc             | Ph.Eur.                          |                    |                                         |                                             |
| Macrogol8000     | Ph. Eur.                         |                    |                                         |                                             |
| Titanium Dioxide | Ph.Eur.                          |                    |                                         |                                             |
| Iron OxideYellow | Directive 95/45/EC (E172)        |                    |                                         |                                             |

posology is 160 mg once daily,with the potential to reduce to 120or 80 mg depending on side effects and tolerability. The applicant is proposing to introduce an alternative formulation, film-coated tablets, containing either40or80mgenzalutamideinordertoreduce thenumber andsizeof dailydosageunits.

Enzalutamide is a crystalline BCS class II (low solubility, high permeability) substance with low aqueous softcapsulescircumventthisissuebyhavingtheactivesubstancealreadydissolvedinthecapsulecontents. Inordertoenhancethesolubilityoftheactivesubstanceandensurerapidandcompletedissolutionfroma to initiating the development program, a quality target product profile (QTPP) was defined (table 3).

Table3:QTPPforenzalutamide tablets

| Items                 | Target                                          |
|-----------------------|-------------------------------------------------|
| Dosage form           | Film-coated tablet                              |
| Routeofadministration | Oral                                            |
| Dosage form strength  | 80 mg and 40 mg                                 |
| Pharmacokinetics      | Bioequivalent to the liquid-filled soft capsule |
| Stability             | Stable for atleast 2 years at 25°C.             |

This was then used toidentify critical quality attributes (CQAs) of thefinished product which would ensure the robust performance of the tablets (table 4).

Table 4:cQAs of enzalutamide tablets

| Critical QualityAttribute   | Target                                                                                                |
|-----------------------------|-------------------------------------------------------------------------------------------------------|
| Appearance                  | Oval,yellowfilm-coated tabletwith debossing (80 mg) Round,yellowfilm-coated tabletwithdebossing(40mg) |
| Assay                       | 95.0% -105.0%                                                                                         |
| Uniformity of dosage units  | Meets Ph.Eur.2.9.40                                                                                   |
| Dissolution                 | ImmediateRelease                                                                                      |
| Degradants                  | MeetsICHguideline Q3B(R)                                                                              |
| Residual solvent(Acetone)   | MeetsICHguideline Q3C (R)                                                                             |
| Hardness andfriability      | handling.                                                                                             |

<div style=\"page-break-after: always\"></div>

Variouspolymerswereinvestigatedasadditivespriortospray-dryinginordertostabiliseamorphous enzalutamideandtoenhancethedissolutionrateofthedispersedactivesubstance.Hypromelloseacetate succinate(HPMCAS)wasfound toofferexcellentstabilityoftheactivesubstanceinitsamorphousstate whilstensuringrapidandcompletedissolutionandwasselectedforfurtherdevelopment.Drugloadingwas next investigated and a level of 4.2 wasselectedbasedonthepharmacokinetic(Pk)profilesofthe differentloadingsinvestigated.

StabilitystudiesfortheenzalutamideSDDintermediatestoredinbulkwereperformedundercontrolledroom storedat40°C/75%RHforupto6months.Theseresultssupporttheconclusionthatthecomponentsused the active substance.The proposed holding time of 12 months for enzalutamide SDD in the proposed packaging is acceptable.

A risk assessment was then carried out using failure mode effects analysis (FMEA) to assess properties of the HPMCASpropertiesondissolutionwasidentifiedashighrisk.Differentacetateandsuccinatesubstitution polymer.FinishedproductbatchesmanufacturedwithdifferenttypesofHPMCASwerecomparedin dissolution and in relative bioavailability studies. Both tablets showed a rapid and complete dissolution within 30 minutes, regardless of the HPMCAS used. The AUC and the Cmax values obtained confirmed that the HPMcAS attributes have little to no impact on the in vivo pharmacokinetics of this product.

The enzalutamide SDD is a low bulk density poorly flowing powder. However, addition of liquids to the formulation risks generating crystalline material. Therefore, a dry granulation approach was pursued for methodology. However, the relative amounts had little impact on dissolution rate. All excipients are well national formulary(NF)standards.Therearenonovelexcipientsused inthefinishedproductformulation.

glassvialsateither50oC/ambientRHor40oC/75%RHforonemonth.Theblendswerethenevaluated for their appearance, assay and related substances. No significant changes were observed, indicating that the tabletexcipientsselectedarecompatiblewiththeSDDintermediateandthattheydonotimpactthecritical qualityattributesorstabilityofthisproductundernormalstorageanduseconditions.

bulk density and particle size were identified as having the biggest risk so tablets were prepared using batches of SDDwith differentbulk densities and particle sizes.However,noimpacton dissolution performance was observed. Therefore, it was concluded that none of the tablet CQAs is impacted by any of intermediatehavebeenset.

Inorder todevelopadiscriminatorydissolutionmethodforqualitycontrol(QC),variousparameterswere investigated including medium pH and agitation rate.Studies were carried out on the 80 mg tablet. In the

<div style=\"page-break-after: always\"></div>

presence of HPMCAS,greater dissolution of the active substance occurs athigherpH.A medium of pH7.5 formulationwithin30minutes.Significantdifferenceswereseenbetweenthecommercialformulationand batches with different drug loadings and where differentfillers were used.Differences were also noted properties of the active substance, the method is considered to be sufficiently discriminatory.

The dissolution profile of the 80 and 40 mg tablets were compared in 0.1 M HCl, pH 4.5 acetate buffer, pH Bioequivalencebetween the capsule and tabletformulationwas demonstrated in clinical studies as the dissolutionprofilesoftheformulationsweresignificantlydifferentacrossallmediainvestigated.

AseriesofriskassessmentsandsubsequentDoEswerecarriedoutinordertoidentifycriticalprocess parameters in each step of the manufacturing process. Suitable parameters were identified for spray drying, granulation, final blending and compression. The impact of the ranges studied on the tablet CQAs was found tobelowandnocriticalstepswereidentified.Theset-pointsandrangesforprocessparametersineachstep ofthemanufacturingprocesshavebeenadequatelyjustified.

section6.5oftheSmPC.ThematerialscomplywithPh.Eur.andECrequirements.Thechoiceofthe containerclosuresystemhasbeenvalidatedbystabilitydataandisadequatefortheintendeduseofthe product.

## Manufactureoftheproductandprocesscontrols

The manufacturing process consists of 2 parts: production of the enzalutamide SDD intermediate which is second.ThemanufacturingprocessoftheSDDintermediateconsistsofdissolutionoftheactivesubstance and HPMCAS in acetone, spray drying and secondary drying (scheme 1). The batch is divided into 2 subbatchesfor thesecondarydryingoperation.Thein-processcontrolofacetonecontentandspecificationsof the SDD intermediate are adequate to ensure quality.As discussed in the pharmaceutical development section,theproposedpackagingandholdingtimefortheSDDhasbeenjustifiedbystabilitydataandis consideredacceptable.

Scheme 1: manufacturing process for enzalutamide SDD

<!-- image -->

<div style=\"page-break-after: always\"></div>

AGMPinspectionoftheSDDmanufacturerrevealedtwocriticalandonemajordeficienciesrelatingtodata integrity. Major deficiencies were also found with hygiene, identification of equipment and validation. In addition,issues from previous inspections had not been addressed. As a result, the validity of the data assessmentofthevalidityofdatasubmittedinthedossier.

A risk assessment was conducted by the applicant's quality assurance department, focussing on product used in clinical studies and to support quality development. The detailed risk assessment was submitted to therapporteur'steamandassessed.Itwasconcludedthattheapplicanthadadequatelyaddressedall potential risks and that measures were inplace to mitigate and reduce themto anacceptablelevel. Therefore,there is no evidence to question the validity of the data submitted in this line extension application.

The manufacturing process for the tablets (scheme 2) consists of six main steps: blending of intra-granular excipients; granulation(roller compaction);blending with extra-granular excipients; compression;filmcoating; packaging.The process is considered to be a standard manufacturing process.

Scheme2:manufacturingprocessforenzalutamidefilm-coated tablets

<!-- image -->

The applicant has justified the set-points and any associated ranges for process parameters using results from DoEs. However, no design space is claimed, despite the multi-variate experimental results.

<div style=\"page-break-after: always\"></div>

An acceptable process validation scheme has been submitted and the process will be validated on three consecutive production scale batches of finished product prior to commercialisation.From the batches manufactured to date, it has been demonstrated that the manufacturing process is capable of producing finished product of intended quality in a reproducible manner. The in-process controls are adequate for this

## Productspecification

The finished product release specifications (Table 5) include appropriate tests for this kind of dosage form including description, identity (HPLC, UV), assay (HPLC), degradants (HPLC), uniformity of dosage units (Ph. Eur.), dissolution (HPLC) and microbial limits.

Table5:specificationsfor finishedproduct

<!-- image -->

ImpurityBisnotpresentintheactivesubstancebutisbothanoxidativedegradantfoundinenzalutamide40 mg and 80 mg tablets and a metabolite. The wider shelf-life limit is justified given the increase in the solventcontentisneededasatestforacetonecontentisperformedontheSDDintermediate.Notestfor

<div style=\"page-break-after: always\"></div>

watercontentisincludedasverylittleincreaseinwatercontentwasobservedinstabilitystudies.Opendish attributes.

Theabsenceofatestforphysicalformhasbeenadequatelyjustified.Enzalutamidetabletsaredesignedto containamorphousactivesubstanceandnocrystallizationhasbeendetectedinhistoricalbatches.

The analytical methods used have been adequately described and appropriately validated in accordance with testinghasbeenpresented.

confirming theconsistencyofthemanufacturingprocessandits abilitytomanufactureto theintended product specification.

## Stabilityoftheproduct

Stabilitydatafrom3pilotscalebatchesofeachstrengthoffinishedproductstoredunderlongterm /  ) s  s     o  o ) s accordingtotheICHguidelineswereprovided.Upto24months'dataisavailableforthe80mgtablets whereas18months'dataisavailablefor40mgtablets.Thebatchesweremanufacturedatthecommercial marketing.

Samples were tested for description, assay, degradants, dissolution, microbial limits, water content (KF) and physicalform(NIRs,XRPD).Theanalyticalproceduresusedare stabilityindicating andthosenotinthe release specification (KF and NIRs) were validated. No significant changes in appearance,assay, dissolution, microbiallimitorphysicalformwereobservedwhenstoredatthelongtermandacceleratedconditions.The However, no impact on other product attributes resulted. The wider shelf-life impurity limits are considered justified.A statistical analysis of trends was conducted indicating that impurity levels will remain within specificationforover36months.

ResultsarealsoreportedfrombatchesstoredinopenHDPEbottlesathighertemperature(5o°C,ambient an increase in water content and impurity B, within shelf-life limits. More impurity B is formed in the open bottlesascomparedtotheblisters.

in either aluminium pouches or HDPE drums. Samples were stored between 15-30 °C and 35-65% RH for up acceptable.

Based on available stability data, the proposed shelf-life of 36 months without special storage conditions as statedintheSmPC(section6.3)isacceptable.

<div style=\"page-break-after: always\"></div>

## Adventitious agents

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the finished product has beenpresented in a quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.The risk assessment provided by the applicant to address GMP deficienciesattheSDDmanufacturerleadstotheconclusionthatthevalidityofdataprovidedinthedossier to support the line extension should not be questioned.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The qualityof thisproduct is considered tobe acceptablewhenused in accordancewith theconditions theproducthavebeeninvestigated andarecontrolled ina satisfactoryway.

## 2.2.6. Recommendations for future quality development

Not applicable.

## 2.3.Non-clinicalaspects

Nonewnon-clinicaldataweresubmittedinsupportofthisapplicationwhichisconsideredacceptable.

## 2.3.1.Ecotoxicity/environmentalriskassessment

Thetargetdiseaseindicationinthecurrentlineextensionapplicationshasnotchanged,andthenewtablet formisnotexpectedtoresultinanincreaseintheenvironmentalexposure.TheMAH'sjustificationfornot providing an updated ERA is considered acceptable.

## 2.3.2. Discussion on non-clinical aspects

Nonewdataweresubmittedaspartofthisapplicationwhichisconsideredacceptableconsideringthescope of this procedure.Any unused medicinal product or waste material should be disposed of in accordance with local requirements as already mentioned in the current wording of the SmPC, section 6.6.

## 2.3.3. Conclusion on the non-clinical aspects

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

TheClinicaltrialswereperformedinaccordancewithGCPasclaimedbytheMAH.

## Tabularoverviewofclinicalstudies

|                                   | Single-dose Studies(160 mg)   | Single-dose Studies(160 mg)   | Single-dose Studies(160 mg)   | Single-dose Studies(160 mg)   | Multiple-dose Study (160mg/dar)   |
|-----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------------|
| Design Feature                    | Srudy ADV3100-05              | Stndy 9785-CL-0010            | Srudy MDV3100-19              | Study 9785-CL-0014            | Study 9785-CL-0003                |
| Study report locafion             | Module5.3.1.2]                | Module53.12]                  | [Module 53.1.2]               | [Module5.3.1.2]               | Module53.1.2]                     |
| Tablet formuiation                | TabletA                       | Tablets Band C                | TabletsE andF                 | To-be-marketed tablet         | TabletA                           |
| Tablet strength                   | 160mg                         | 80mg                          | 80mg                          | 80mg                          | 160mg                             |
| PK objectives                     | Relative BA and foodeffects   | Relative BA                   | Relative BA                   | Pivotal BEand foodeffects     | Relative BA and foodeffects       |
| Subjects                          | Healthy males                 | Healthy males                 | Healthy males                 | Healthy males                 | CRPCpatieats                      |
| No.of sabjects teated             | 60                            | 55                            | 4$                            | 59                            | 27                                |
| Food conditions                   | Fasted and fed                | Fasted                        | Fasted                        | Fasted and fed                | Fasted and fed                    |
| Design for formlation companison  | 2-period crossover            | 1-perniod, paallel group      | l-period, parallelgroup       | 2-peniod crossover            | 1-period, arallel gop             |
| Design for food-effect comparison | Paallel group                 | NA                            | NA                            | Parallel grouy                | Crosaover                         |
| Duration ofPKsampling             | 41 days postdose              | 49 days postdose              | 28 days postdose              | 20.48 days postdose           | 24houurspostdose                  |

## 2.4.2. Pharmacokinetics

Foursingledoseandonemultipledosestudiesweresubmitted(seetableabove).Thesestudiesassessed the pharmacokinetics of enzalutamide either after a single-dose or after multiple-dose administration at 160 mg/day. Four of these studies assessed the relative bioavailability of various tablet formulations (MDv310005,9785-CL-0010,MDV3100-19,9785-CL-0003) and one was a pivotal bioequivalence study(9785-CL0014)oftheto-be-marketedtablet.Food-effectanalysesweretestedwithintwooftherelativebioavailability studies (MDV3100-05 and 9785-CL-0003), as well as the pivotal bioequivalence study (9785-CL-0014).

An analysis based on simulated pharmacokinetics data to assess steady-state Cmax and exposure-response analysisfromCRPC2wasalsoconducted.

## RelativeBioavailability

Single-doseStudies

StudyMDV3100-05,RelativeBioavailabilityandFood-effectofTabletA

This study was a pilot phase 1，single-center,open-label,randomized，2-period cross-over relative bioavailability and food-effect study following a single 160 mg dose of enzalutamide in healthy male subjects. The objectives were to compare Tablet A to the capsule under fasted and fed conditions and to assess food effectsforTabletAandthecapsule.

<div style=\"page-break-after: always\"></div>

TheApplicantconducted2x2cross-overstudies(onefastedandonefed)toobtainestimatesofinter-and intra-subject variability to adequately power future bioequivalence studies. The minimum 6-week washout subject variability in PK is low (≤ 33.3%CV in this study).

The totalcaloric contentwas917kcal,ofwhich547kcal(59.6%)was due tofat,116kcal(12.7%o)due to proteins and 254 kcal(27.7%) due to carbohydrates.

## Results

The results showed that, regardless of food condition (fasted or fed), the extent of absorption (as reflected by AUCiast and AUCinf) was similar for Tablet A versus the capsule, and the rate of absorption (as reflected by the lower Cmax and later tmax) was slower with Tablet A than the capsule. Based on GMR, Cmax was approximately fed conditions

In the food effects assessment, administration of the capsules after high-fat, high-caloric breakfast, resulted in a 30% reduction in Cmax compared to the fasted conditions, while AUC was not affected.

affectedbyformulation.

In both fated and fed conditions, the 90% CIs for AUCo-t, AUCo-inf, and Cmax were all within the predefined equivalence criteria limit (80.00%, 125.00%), indicating that both the total and peak exposures for MDPCooo1andMDPcooo2mettheacceptancecriteriaformetabolitesexposure.

Exploratory metabolite equivalence and food-effects analyses for metabolites MDPCooo1 and MDPCo002 to these metabolites

Study9785-CL-0010,RelativeBioavailabilityofTabletsBandC(EudraCTnumber2012-002502-49)

This was a phase 1, single-center, open-label, randomized, parallel group, relative bioavailability study following a single 160 mg dose of enzalutamide in healthy male subjects. The objectives were to compare TabletBandTabletCtothecapsuleunderfastedconditions.

s! h! pue uasoup sm uaisap dnob jallined e '(shep g'sr) apiweniezua jo a!l-giy uoeuiwa buol aun on ana considered acceptable. However, AUCo-72 is not able to predict the results obtained for AUCo-t and AUCo-infThereforetheuseofAUCo-tandAUCo-infisnecessary.

## Results

Basedontheresults，theTabletBformulationwasnotbioequivalenttothecapsuleformulation. Enzalutamide AUCo-t and AUCo-inf were similar to the capsule formulation, although Cmax and AUCo-72h were 46.40% and 23.75%, respectively, lower compared to the capsule. Interestingly, AUCo-72h data show that the absorption is not complete after 3 days since it is not predictive of AUCo-t and AUCo-inf.

TheTabletCformulationwasalsonotbioequivalenttothecapsuleformulationsincethetotalexposurewas slightly above the acceptance criteria for bioequivalence and peak exposure (Cmax) was below. Enzalutamide

<div style=\"page-break-after: always\"></div>

AUCo-t and AUCo-inf were approximately 10% higher compared to the capsule formulation. Cmax and AUCo-72h were18.44%and13.62%,respectively,lowercomparedtothecapsule.

For the enzalutamide metabolite M1, generally comparable AUCo-t, AUCo-inf and Cmax geometric mean values forthecapsuleandbothtabletformulationswereobserved.

For the enzalutamide metabolite M2, comparable AUCo-t and AUCo-inf geometric mean values for the capsule and both tablet formulations were observed, while Cmax was 22.6% and 18.5% lower for Tablet B and Tablet C, respectively.

For the sum of enzalutamide plus its metabolite M2, AuCo-t geometric mean value was comparable for the t s a  e x a ss  o  s TabletB and Tablet C,respectively.

## StudyMDV3i00-19,RelativeBioavailabilityofTabletsEandF

This was a phase 1, single-center, open-label, randomized, parallel group, relative bioavailability study following a single 160 mg dose of enzalutamide in healthy male subjects.The objectives were to compare TabletEandTabletFtothecapsuleunderfastedconditions.

## Results

(reference), the 90% CIs for AUCo-t, AUCo-72 and AUCinf were fully contained within the typical boundaries for bioequivalence(0.8000and1.2500);however,thelowerrangeofthe90%CIforCmaxforbothtabletswas below the boundary for bioequivalence(0.8ooo).Based on the geometric mean ratios, the Cmax of tablet E was 18.66% lower than that of the capsule, and the Cmax of tablet F was 16.81% lower than that of the therateofabsorptionofenzalutamidewiththetablets.

## Multiple-doseStudies

## Study9785-CL-0003,relativebioavailabilityandfood-effectofTabletA

This was a phase 1, multicenter, open-label, randomized, one-period relative bioavailability and food-effect weretocompareTabletAtothecapsuleunderfastedandfedconditionsandtoassessfoodeffectsforTablet A and thecapsulewithenzalutamidedosedtosteadystate.

enzalutamide AUCtau and Ctrough for the tablet and capsule formulations were comparable.

In this study the composition of the meal varied between sites and the composition of the meals is in accordance with the Guideline on investigation of bioequivalence that requires approximately 150, 250, and 500-600kcalfromprotein,carbohydrate,andfat,respectively.

After multiple 160 mg doses of enzalutamide, compared to the capsule formulation, the Cmax of the tablet respectively.

NoeffectoffoodonenzalutamideCmaxforeitherthetabletorcapsulewasobserved.

<div style=\"page-break-after: always\"></div>

In addition, an exploratory assessment to determine whether Tablet A differs from the capsules with regard stateexposurestoN-desmethylenzalutamidewereessentiallythesameforthetabletandcapsule formulations, regardless of food condition.

## Bioequivalence

## StudyProtocolNumber:9785-CL-0014(EudraCTnumber2014-002641-21)

This is a pivotal phase 1, single-center, open-label, 2-period, crossover bioequivalence study comparing a s n        o    s conditionsinhealthymalesubjects.

The total caloric contentwas 982kcal,of which 590kcal(60%)was due tofat,125 kcal(13%)was due to proteins and268kcal(27%)wasdue tocarbohydrates.

## Results

## Table 6:Summary ofthe statisticalcomparisons ofthe formulations arepresented in the following table (all subjects)

| Fasted Conditions                               | Fasted Conditions                            | Fasted Conditions    | Fasted Conditions          | Fasted Conditions    | Fasted Conditions    |
|-------------------------------------------------|----------------------------------------------|----------------------|----------------------------|----------------------|----------------------|
| Enzalutamide Parameters (Units)                 | GeometricMeans                               | GeometricMeans       | Ratio (%)                  |                      |                      |
| Pharmacokinetic                                 | To-be-marketed Tablet (Iest)                 | Capsule (Reference)  | (Test/Reference)           | 90% CI for Ratio (%) | 90% CI for Ratio (%) |
|                                                 |                                              |                      |                            | Lower                | Upper                |
|                                                 | 29                                           | 27                   | 、                          |                      |                      |
| AUCo.2a(μg-h/mL)                                | 102                                          | 105                  | 97.26                      | 95.13                | 99.43                |
| AUCs(ug-h/mL)                                   | 225                                          | 223                  | 100.94                     | 96.26                | 105.84               |
| AUCin(μgh/mL)                                   | 235                                          | 232                  | 101.17                     | 96.77                | 105.77               |
| Cmx(μg/mL)                                      | 3.39                                         | 4.71                 | 71.82                      | 66.75                | 77.28                |
| t(h)+                                           | 2.00[0.50-6.02]                              | 1.00[0.50-3.02]      | **                         |                      |                      |
| Fed Conditions                                  | Fed Conditions                               | Fed Conditions       | Fed Conditions             | Fed Conditions       | Fed Conditions       |
|                                                 |                                              |                      |                            | 90%CIforRatio (%)    | 90%CIforRatio (%)    |
| Enzalutamide Pharmacokinetic Parameters (Units) | Geometric Means To-be-marketed Tablet (Test) | Capsule (Reference)  | Ratio (Test/Reference) (%) | Lower                | Upper                |
|                                                 | 28                                           | 28                   |                            |                      |                      |
| AUCoz2a(μg-h/mL)                                | 102                                          | 106                  | 95.56                      | 88.35                | 103.35               |
| AUC(ug-h/mL)                                    | 250                                          | 267                  | 93.56                      | 84.34                | 103.78               |
| AUCm(μg-h/mL)                                   |                                              | 276                  | 93.75                      |                      | 103.11               |
|                                                 | 259                                          |                      |                            | 85.25 79.94          | 101.36               |
| Cmax(μg/mL) tox（h)t                             | 2.68 3.00 [0.50-8.03]                        | 2.97 2.99[0.50-8.00] | 90.01                      |                      |                      |

AUCo2:area under the concentration-time curve from time point 0 to time point 72 hours, AUC area under the concentration-time curve from the timeof dosing extrapolated to time infinity,AUCs:areamnder the concentration-time curve from the time of dosing to the last measurable concentration: Cmax:maxinum concentration; CI: confidence interval, n: sample size:aa time to attain maximum concentration.

<div style=\"page-break-after: always\"></div>

Table7:StatisticalSummary ofFood-EffectComparisonforEnzalutamidefor the Tablet Formulation

| Enzalutamide Parameters   | Geometric Mleans          | Geometric Mleans             |                           | 90% CI for Ratio   | 90% CI for Ratio   |
|---------------------------|---------------------------|------------------------------|---------------------------|--------------------|--------------------|
| Pharmacokinetic           | To-be-marketed Tablet-Fed | To-be-marketed Tablet-Fasted | Ratio (Iest/Reference) () | (%0)               | (%0)               |
| (Units)                   | (Test)                    | (Reference)                  |                           | Lower              | Upper              |
| n                         | 28                        | 28                           |                           |                    |                    |
| AUCoz (μg h/mL)           | 102                       | 102                          | 99.24                     | 88.91              | 110.76             |
| AUCtos (μg-h/mL)          | 250                       | 225                          | 111.01                    | 96.78              | 127.33             |
| AUCr(ugh/mL)              | 259                       | 234                          | 110.64                    | 96.59              | 126.74             |
| Cm(g/mL)                  | 2.68                      | 3.38                         | 79.18                     | 68.58              | 91.43              |
| tx(h)t                    | 3.00[0.50-8.03]           | 2.00 [0.500-6.02]            | *                         |                    |                    |

AUCoarea under the concentration-tme curve from time point 0 to time point 72 hours,AUCarea under the concentraton-time curve from the time of dosing extrapolated to timenfinity,AUCsarea under the concentration-time curve from the time of dosing to the last measurable concentration,Cmxmaximum concentration, CI confidence interval,n: sample size,tuax time to aftan maximum concentration.

Valuesreported for Lare the medianand range of observed values (minimum-maximum)

Table 8:Statistical Summary of Food-Effect Comparison for Enzalutamidefor the Capsule Formulation

|                   | GeometricLSMlean   | GeometricLSMlean        | Geometric LS Mean Ratio   | J%06 Ratio    |
|-------------------|--------------------|-------------------------|---------------------------|---------------|
| Parameter (Units) | Fed (Test) n=28    | Fasted (Reference) n=27 | (Test/Reference) (%0)     | (%)           |
| AUCn(ugh/mL)      | 106.3              | 103.6                   | 102.63                    | 94.79-111.12  |
| AUCu(ugh/mL)      | 266.8              | 219.7.                  | 121.44                    | 108.15-136.36 |
| AUCr(ugh/mL)      | 276.1              | 226.2                   | 122.08                    | 108:35-137.54 |
| Cmu (ug/mL)       | 2.972              | 4:693                   | 63.34                     | 56.76-70.69   |

The analysis wasperformed on log-transformedpharmacokineticparameters using ananalysis of variance (ANOVA)model with food condition and period asfixedeffects.

CIconfidence interval, LS:least square,NA:notapplicable

Theformulationcomparisonof the to-be-marketed tabletversus the capsuleunder bothfastedandfed conditions showed that the 90% CI for AUCiast and AUCinf were within the bioequivalence criteria limits, and the 90% CI for Cmax were below the lower boundary for bioequivalence. The 90% CI for AUCo-72h was within thebioequivalencecriterialimitsunderbothfastedandfedconditions.Underfastedconditions,themedian conditions,the median tmax of the tablet was essentially the same as that of the capsule(3.o0versus 2.99 hours).

Takentogether,theresultsoftheformulationcomparisonshowedthat,regardlessoffoodcondition(fasted or fed), the extent of absorption(as reflected by AUCiast and AUCinf)was the same for the to-be-marketed tablet and the capsule, and the rate of absorption (as reflected by the lower Cmax and later tmax) was slower for the tablet. Based on GMR, Cmax was approximately 28.18% lower for the tablet than the capsule under fastedconditionsandapproximately10%lowerunderfedconditions.

<div style=\"page-break-after: always\"></div>

Thefood-effect comparison(fedversusfastedconditions)for theto-be-marketed tablet showedthatthe 90% CI for AuCiast and AuCinf extended slightly above the upper boundary of the bioequivalence criteria limits, the 90% CI for Cmax extended below the lower boundary and AUCo-72h was within the bioequivalence criterialimits.Themediantmaxoccurred1hourlater withfedconditionsthanwithfastedconditions(3.00 versus2.00hours).

The pharmacokinetic exposure parameters of N-desmethyl enzalutamide (AUClast, AUCinf and Cmax) appear not tobe affectedbyformulation orfoodcondition.

Median tmax values were similar for all regimens with peak concentrations reached after approximately 168 hours (i.e., 7 days). Mean t1/2 was comparable after administration of tablet and capsule formulations under fasted and fed conditions and ranged from 174.2 and 195.6 hours (i.e., 7.3 and 8.2 days).

Between subjects variability in N-desmethyl enzalutamide AUCiast, AUCinf and Cmax was low and similar for the differenttreatments,withvaluesrangingfrom12.3%to26.4%.

AUClast and AuCinf of the sum of enzalutamide plus N-desmethyl enzalutamide appear not to be affected by forthesumofenzalutamideplusN-desmethylenzalutamideofthecapsuleunderfedconditionsandof the tabletunderfastedandfedconditionswere35%,31%,and34%lower,respectively.

Under both fasted and fed conditions, median tmax values for the tablet (2.000 hours and 3.500 hours, respectively)were1hourlaterthanforthecapsule(1.oo0hoursand2.490hours,respectively).Forboth formulations,mediantmaxwas1.5hourslaterunderfedcomparedtounderfastedconditions.

Between subjects variability for the sum of enzalutamide plus N-desmethyl enzalutamide AUCiast, AUCinf and Cmaxwaslowforthedifferentregimens,withvaluesrangingfrom16.1%to34.4%.

## Non-parametricsuperposition

Using individual single-dose PK profiles from study MDV3100-05, the Applicant performed PK simulations to steady-statetovalidatethemodel.

The geometric mean valuesfor AUCtauy Cmax and Cmin were similar for the observed data and the data predicted by non-parametric superposition.The geometric mean ratios and corresponding 90% CI for Tablet A versus the capsule were nearly identical for the observed and predicted data(see the table below).

<div style=\"page-break-after: always\"></div>

Table9:SummaryofObservedandPredictedMultiple-doseParametersforTabletAandCapsule underFasted Conditions

|                                               | GeometricMeans                                | GeometricMeans                                | Ratio                                         | 1%06 Ratio (%)                                | 1%06 Ratio (%)                                |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| EnzalutamidePharmacokinetic Parameters(Units) | Tablet A (Test)                               | Capsule (Reference)                           | (Test/Reference) (%)                          | Lower                                         | Upper                                         |
| Observed inMultiple-doseStudy9785-CL-0003     | Observed inMultiple-doseStudy9785-CL-0003     | Observed inMultiple-doseStudy9785-CL-0003     | Observed inMultiple-doseStudy9785-CL-0003     | Observed inMultiple-doseStudy9785-CL-0003     | Observed inMultiple-doseStudy9785-CL-0003     |
| AUCu(μg.h/mL)                                 | 290                                           | 318                                           | 91.19                                         | 82.63                                         | 100.63                                        |
| Cx (lg/mL)                                    | 13.9                                          | 16.9                                          | 82.48                                         | 74.28                                         | 91.60                                         |
| Cmin(μg/mL)                                   | 12.4                                          | 12.8                                          | 97.04                                         | 85.55                                         | 110.07                                        |
| PredictedfromSingle-doseDatainStudyMDV3100-05 | PredictedfromSingle-doseDatainStudyMDV3100-05 | PredictedfromSingle-doseDatainStudyMDV3100-05 | PredictedfromSingle-doseDatainStudyMDV3100-05 | PredictedfromSingle-doseDatainStudyMDV3100-05 | PredictedfromSingle-doseDatainStudyMDV3100-05 |
| AUCu(Hgh/mL)                                  | 262                                           | 279                                           | 94.03                                         | 81.97                                         | 107.86                                        |
| Cmx(μg/mL)                                    | 12.7                                          | 15.4                                          | 82.81                                         | 73.53                                         | 93.28                                         |
| Cmin (μg/mL)                                  | 9.9                                           | 10.3                                          | 96.53                                         | 83.39                                         | 111.75                                        |

AUCuu: area under the concentration-time curve during one 24-hour dosing interval at steady state;

Cuax: maximm concentration; Cmn: minimum (trough) concentration; Cl: confidence intervals

Predictedvalueswere obtained bynonparametricsuperposition.

Takentogether,theresultsofthevalidationstudy，comparisonbetweendataobtainedfromsimulationand theobservedsteady-statedataobtainedfromstudy9785-CL-003 shows that thenon-parametric superposition is good to predict steady-state Cmax since the differences between the observed and predicted for Cmax was &lt; 10%.

## NonparametricSuperpositionofDatafromthePivotalBioequivalenceStudy

Non-parametric superposition was applied to single-dose data from the pivotal bioequivalence study 9785CL-0014todetermineiftheto-be-marketedtabletformulationwouldmeetbioequivalencecriteriaunderthe conditionsofonce-dailydosingtosteadystate

Thesimulatedmultiple-dosedatashowthattheto-be-marketedtabletispredictedtobebioequivalenttothe capsule for AUCtau, Cmax, and Cmin with once-daily dosing in steady state under fasted and fed conditions since the9o%CIfallwithinthebioequivalencecriterialimits.

<div style=\"page-break-after: always\"></div>

Table 1o: Summary of Simulated Multiple-dose Pharmacokinetic Parameters for the Capsule and To-be-marketedTablet

| Formulation   | Food Condition   | Subjects   | Cmin (μg/mL)   | Cimax (ug/mL)   | (b)              | AUCtaw (ug.h/mL)   | Peak-to- trough Ratio   |
|---------------|------------------|------------|----------------|-----------------|------------------|--------------------|-------------------------|
| Tablet        | Fasted           | M=29       | 9.3 (3.3)      | 12.6 (3.6)      | 2.00 (0.50-6.00) | 247 (81)           | 1.39 (0.18)             |
| Capsule       | Fasted           | n=27       | 8.7. (2.6)     | 13.3 (2.9)      | 1.00 (0.50-3.00) | 234 (63)           | 1.58 (0.21)             |
| Tablet        | Fed              | n=28       | 10.4 (2.9)     | 12.9 3.5)       | 2.00 (0.50-6.00) | 269 (72)           | 1.26 (0.11)             |
| Capsule       | Fed              | n=28       | 11.0 (3.0)     | 13.8 (3.2)      | 2.00 (0.50-6.00) | 285 (73)           | 1.28 (0.12)             |

Results are for the capsule and to-be-marketed tablet in Study 9785-CL-0014

Mean values (standard deviations in parentheses) are reported forall parameters except for fusfor which median and range (mininum-maximum) values are reported.

AUCarea under the concentration-time curve during one 24-hour dosing interval at steady state:

Camaximum concentration: Cmnmum (trough) concentrationn number of subjects; tmaytime to attain maximum concentration.

Thestatisticalcomparisonofthepredictedsteady-stateparametersfortheto-be-marketedtabletversusthe capsuleformulationshowedthatunderbothfastedandfedconditionsispresentedbelow.

Table11:Statisticalcomparisonofthepredictedsteady-stateparametersfortheto-be-marketed tabletversusthecapsuleformulation

| Fasted Conditions                       | Fasted Conditions     | Fasted Conditions   | Fasted Conditions          | Fasted Conditions   | Fasted Conditions   |
|-----------------------------------------|-----------------------|---------------------|----------------------------|---------------------|---------------------|
| Enzalutamide Pharmacokinetic Parameters | GeometricMeans        | GeometricMeans      | Ratio (Test/Reference) (6) | 90% CIfor Ratio     | 90% CIfor Ratio     |
|                                         | To-be-marketed Tablet | Capsule             | Ratio (Test/Reference) (6) | (0)                 | (0)                 |
| (Units)                                 |                       | (Reference)         | Ratio (Test/Reference) (6) | Lower               | Upper.              |
|                                         | (Test)                |                     |                            |                     |                     |
|                                         | 29                    | 27                  |                            |                     | *                   |
| AUC (ughmL)                             | 235                   | 232                 | 61101                      | 96.75               | 105.83              |
| C(ug/mL)                                | 12.09                 | 13:29               | 90.94                      | 87.06               | 95.00               |
| Cam(ug/mL)                              | 8.76                  | 8.56                | 102.35                     | 97.53               | 107.42              |
| （h）t                                    | 2.00[0.50-6.00]       | 1.00[0.50-3:00]     |                            |                     |                     |
| Fed Condinons                           | Fed Condinons         | Fed Condinons       | Fed Condinons              | Fed Condinons       | Fed Condinons       |
| Enzalutamide                            | Geometric Means       | Geometric Means     |                            | 90% CIfor Ratio ()  | 90% CIfor Ratio ()  |
| Pharmacokinetic Parameters (Units)      | To-be-marketed Tablet | Capsule (Reference) | Ratio (Test/Reference) (9) | Lower               | Upper               |
| n                                       | (Test)                | 28                  |                            |                     |                     |
| AUC(ug hmL)                             | 28 259                | 276                 | 93.70                      | 85.13               | 103.12              |
| C(ugmL)                                 | 12.43                 | 13.47               | 9230                       | 83.92               | 10151               |
| C（ug/mL)                                | 9.92                  | 10.59               | 93.66                      | 85.15               | 103.03              |
| (h)f                                    | 2.00[0.50-6.00]       | 2.00[0.50-6.00]     |                            |                     |                     |

AUCarea uder the concentration-time curve from the tinie of dosing extrapolated to time infinity,C maximm concentration, Cminmm concenration, Cl confidence interval, n sample size,time to attanmaximum concentration.

<div style=\"page-break-after: always\"></div>

## Exposure-responseanalyses

CRPc2,inwhichatotalof1199patientswithmetastaticcastration-resistantprostatecancerwere randomized2:1toenzalutamide(n=800)orplacebo(n=399).Thedoseofenzalutamidewas160mg/day (4× 40mg capsules/day).Predose(Cmin)plasma sampleswereobtained fromallpatients toassessplasma concentrations of enzalutamide and its major metabolites. The primary efficacy endpoint was overall survival. radiographicprogression-freesurvival,timetofirstskeletal-relatedeventandPSAresponserate(5o%and 90%reductionsfrom baseline). The analysis of exposure-response between enzalutamide Cmin values and efficacy showed a consistency of results favouring enzalutamide therapy across all primary, key secondary, othersecondaryandexploratoryefficacyendpoints.

Exposure-responseanalysesexploredrelationshipsbetweenenzalutamideCminvaluesandefficacyendpoints (overallsurvival,radiographicprogression-freesurvival,timetoPsAprogressionandseveralotherclinical endpoints).TheCminvalueswereevaluatedascontinuousanddiscreteparameters.Whenevaluatedas discreteparameters,theCminvalueswereclassifiedintoquartiles(Q)thatdividedthederivednonzero exposurequartile(Q4)aftersortingbyrankorder.Exposurecategoriesincludedtheplacebo-randomized patientsas1category(Cmin=0)and4categories(quartiles)ofexposurefortheenzalutamide-randomized patients.

Table12:SummarystatisticsforCminexposurequartilesinstudyCRpc2

| Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   | Cmin(ng/mL) Quartile   |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Q1                     | Q1                     | Q1                     | Q2                     | Q2                     | Q2                     | Q3                     | Q3                     | Q3                     | Q4                     | Q4                     | Q4                     |
| N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               |
| 192                    | 8.93                   | 0.56 10.15             | 190                    | 10.83                  | 10.16, 11.57           | 161                    | 12.18                  | 11.57, 12.96           | 190                    | 14.40                  | 12.97, 22.80           |

Cmn minimum (trough) concentration Max: maximm: Min minimum; N: mumber of subjects, Q: quartile

Log-ranktestsforhomogeneityassesseddifferencesbetweenKaplan-Meierexposurecategorycurves,and pairwise log-rank tests compared exposure categories to one another.In addition, a Cox proportional hazard analysisofCminasacontinuousvariableassessedtheassociationbetweenexposureandeventrisk.Where a statistically significant slope was observed,pairwise Coxproportional hazard estimates compared exposure adjustmentsmadeformultiplicity.

<div style=\"page-break-after: always\"></div>

overallsurvivalwiththecapsuleformulationinstudyCRPC2

<!-- image -->

Inallpairwisecomparisonsversusplacebo,theeffectsoftheactivetreatmentCminquartilegroupswere statisticallysignificant(P0.o039)infavourofactivetreatment.

Allassessments ofefficacyendpointsversus enzalutamideCminvaluesasa continuousvariableresulted in exposure and improved prognosis for patients, pairwise tests showed no difference in the risk of events among active treatment Cmin quartiles (P ≥ 0.5499).

Steady-stateCminconcentrationsofenzalutamidemeasuredinStudy9785-CL-0003(TabletA),and dosedatafromstudiesMDV3100-05(TabletA)and9785-CL-0014(to-be-marketedtablet)weregraphically plots,values for all tabletformulationswerewithin the range of Cminvalues observed with the capsule in study CRPC2. In addition, a tabulation of data from studies CRPC2 and 9785-CL-0014 [see Table below] showsthatthepredictedCminconcentrationsfortheto-be-marketedtabletarebothsimilartothoseforthe capsule formulation and within the range of values associated with clinical benefit in the phase 3 study CRPC2.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Cmin:minimum (trough)concentration;TBM:to-be-marketed Cmin values forthe capsule in studies CRPC2 and correspondsto themedian;diamond symbols correspond to the arithmeticmeans;lowerandupperedgesofthe boxescorrespondtothe25thand75thpercentiles,respectively;whiskerscorrespondtotheminimumand maximumobservedorpredictedvalues

Figure 2:Comparisons of Cmin at steady statefor capsuleversus tabletformulations

|         | Cmiu (μg/mL)   | Cmiu (μg/mL)          | Cmiu (μg/mL)                      |
|---------|----------------|-----------------------|-----------------------------------|
|         | CRPC2? Capsule | 9785-CL-00142 Capsule | 9785-CL-0014 To-be-marketedTablet |
| N       | 763            | 27                    | 29                                |
| Mean    | 11.62          | 8.71                  | 9.30                              |
| Median  | 11.57          | 8.57                  | 8.80                              |
| SD      | 2.57           | 2.57                  | 3.32                              |
| Min,Max | 0.56,22.80     | 3.43,14.7             | 3.39,18.3                         |

Anexposure-responseanalysiswas also conductedforsteady-stateCmax.Themethodswereidentical to thoseoftheanalysisbasedonCmin.Cmaxvaluesinindividualpatientswereestimatedbypopulation pharmacokinetic modeling as described in(Medivation 02 Apr 2014). The summary statistics for the enzalutamide estimated Cmax exposure quartiles are summarized in[Table below].

Table 14: Summary statistics for Cmax exposure quartiles in study CRPc2

| Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   | Cuax (ng/mL)Quartile   |
|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Q1                     | Q1                     | Q1                     | Q2                     | Q2                     | Q2                     | Q3                     | Q3                     | Q3                     | Q4                     | Q4                     | Q4                     |
| N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               | N                      | Median                 | Min, Max               |
| 189                    | 11.19                  | 5.21, 12.27            | 189                    | 13.04                  | 12.29, 13.73           | 189                    | 14.36                  | 13.74, 15.23           | 189                    | 16.72                  | 15.24, 23.07           |

<div style=\"page-break-after: always\"></div>

Kaplan-Meierplotsshowaclearseparationintheplacebogroupfrom allcurvesassociatedwith enzalutamide Cmax groups [Figure below]. A significant difference between the Kaplan-Meier group curves of overall survival(placeboversus active treatmentin any quartile)was demonstrated by alog-rank testfor homogeneity of enzalutamide exposure categories (P&lt; 0.0001). Significant differences (P&lt; 0.0003) were s Cmaxquartileswhencomparedtoeachother.Nodifferencesinsurvivalcurveswereidentified(P&gt;0.5841)

<div style=\"page-break-after: always\"></div>

dose data from Studies MDV3100-05 (Tablet A) and 9785-CL-0014 (to-be-marketed tablet) were graphically compared to Cmax concentrationsin thepivotal phase3 study CRPC2[Figurebelow].

ValuesforalltabletformulationsarewithintherangeofCmaxvaluesobservedwiththecapsuleinthepivotal phase 3 study CRPC2.In addition, a tabulation of data from CRPC2 and 9785-CL-0014[Table below] showed thatthepredictedsteady-stateCmaxconcentrationsfortheto-be-marketedtabletwerebothsimilartothose for thecapsuleformulation andwithin therange ofvalues associatedwith clinical benefit inthe phase 3 study.

<!-- image -->

Cmax:maximum concentration,TBM.to-be-mauketed

Cmax values for the capsule in study CRPC2were simulated by population pharmacokineticmodeling. Cmas values for study 9785-CL-0003were observedin patients.All other Cauxvalueswere derived from nonparametnic superposition of sngle-dose data from the shudies named in the x-axis.Line n themiddleof each box coresponds to themedian:diamond symbols correspond to thearithmetic means, lower and upper edges of the boxes comrespond to the 25and 75 percentiles,respectively,whiskers corespond to the mnimum andmaximum observed orpredictedvalues.

Figure 5:Comparisons of Cmax atsteadystatefor capsuleversus tabletformulations

Table 1: Comparison of steady state Cmax values for capsules versus the to-be-marketed tablet

|         | Cuax（μg/mL)   | Cuax（μg/mL)           | Cuax（μg/mL)                       |
|---------|---------------|-----------------------|-----------------------------------|
|         | CRPC2 Capsule | 9785-CL-0014$ Capsule | 9785-CL-0014 To-be-marketedTablet |
| N       | 756           | 27                    | 29                                |
| Mean    | 13.88         | 13.32                 | 12.55                             |
| Median  | 13.74         | 13.13                 | 12.17                             |
| SD      | 2.49          | 2.86                  | 3.62                              |
| Min,Max | 5.21,23.07    | 7.90,19.7             | 6.87,21.7                         |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

No data submittedwhich is considered acceptableconsidering the scope of thisprocedure.

## 2.4.4. Discussion on clinical pharmacology

The clinical data submitted in support of the Marketing Authorisation of a new film-coated (FC) tablet formulation of Xtandi, i.e. 80 mg and 40 mg tablets is considered acceptable and in line with the CHMP ScientificAdvicethatwasgiven.

Althoughthesestudiesareusuallyconducted atthehigheststrength,theApplicantconducted thestudies at since no major deviations from dose proportionality were detected over the dose range 40 to 160 mg, neither afterasingledosenoratsteadystate(seeXtandiEMA/CHMP/383457/2013).

Pharmacokinetic software and method for AUCo-t and Cmax in the fasting and fed single-dose studies and AUCtau, Cmax and Cmin in the fasting and fed multiple-dose study estimation are considered acceptable. The afastingandfedsingledoseandmultiple-dosebioequivalencestudyofanimmediatereleaseproduct.

TheparentcompoundandmetaboliteM2PKparameterswasusedintheBAstatisticalandfoodeffects PK analysis of enzalutamide parent compound was performed.For M1 PK parameters and food effect comparisons were performed instudies MDV3100-05 and 9785-CL-0010.The use of theparent and M2 circulates at approximately the same plasma concentration as enzalutamide withmultiple dosing of enzalutamidetosteadystate.

The use of non-parametric superposition was discussed with FDA and CHMP, and both agencies agreed that application.

Conventionalandstandardstatisticalmethodshave beenemployed.For non-parametric superposition, statisticalanalyses for bioequivalence at steady stateused the same methods as the prior single-dose bioequivalence comparisons for tablet (test) versus capsule (reference) in study 9785-CL-0014 and this is considered acceptable.

Thebioanalytical method was assessed previously in theinitial MAA EU/1/13/846/001 and it was considered adequate.The storage perioddid not exceed the current validated storage period of 1106days for showedacceptablecalibrationstandardsandQCs.

IncurredSampleReproducibilitywasperformedinallstudies.Forthesamplesreanalysed,theISRwas acceptable as 92.4% and 88.0% of the reanalysed samples for MDV3100 and MDPC0002, respectively,were within the acceptance range (± 20%).

Several enzalutamide tablet formulations (Tablets A, B, C, E and F) were developed and assessed in relative bioavailability studies and according to the MAH, the critical quality attributes were achieved with Tablet E, whichwasselectedastheformulationfortheto-be-marketedtablet.

<div style=\"page-break-after: always\"></div>

Thepivotalbioequivalencestudy(9785-CL-0014）comparedtheto-be-marketedtablettothecapsule formulationaftersingle-doseadministrationofenzalutamide.Underbothfastedandfedconditions,the9o% CI for total exposure(AuC)were within the bioequivalence criteria limits,and the lower range of the9o%CI for peak exposure (Cmax)was below the lower with the to-be-marketed tablet than with the capsule. Under fated condition Cmax was 28% and under fed condition was 10% lower.

Toassesswhethertheto-be-marketedtabletmightmeetallbioequivalencecriteriarelativetothecapsule doseadministration.Thestatisticalcomparisonofthepredictedsteady-stateparametersfor theto-bemarketedtabletversusthecapsuleformulationshowedthatunderbothfastedandfedconditions,the9o% CI for AUCtau, Cmax and Cmin fell within the bioequivalence criteria limits.

Based on GMR, Cmax was approximately 9% lower for the to-be-marketed tablet than the capsule under fasted conditions and approximately 8% lower under fed conditions.Thus, consistent with the established pharmacokineticpropertiesofenzalutamide,theCmaxdifferencesbetweentheformulationsweresmallerwith multiple-doseadministrationtosteadystatethanaftersingle-doseadministration.

Inaddition to supporting assessments of bioequivalence with once-daily dosing to steady state, stateCmaxconcentrationsobtainedbynonparametricsuperpositionofdatafromthepivotalbioequivalence study (9785-CL-0014) were compared with Cmax concentrations generated by pharmacokinetic modeling and be-marketed tablet formulation were within the range of Cmax values observed with the capsule in study CRPC2.

relative to placebo across efficacy endpoints (overall survival, radiographic progression-free survival and time toPSAprogression),itisunlikelythattheto-be-marketedtabletformulationwoulddifferfromthecapsulein terms of efficacy outcomes. Thus, in spite of nonequivalence between tablets and capsule for Cmax in a singledose setting, the clinical effectiveness of the to-be-marketed tablet formulation is expected to be comparable tothatofthecurrentlymarketedcapsule.

These data can be extrapolated to the 40 mg strength as all requirements described in section 4.1.6 of the Bioequivalence guideline are fulfilled (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **).

Given the nature of the non-compliance of the site manufacturing theEnzalutamide SDDand tablet drug productusedintheclinicaltrials,ariskassessmentwasprovided.Itwasconcludedthattheprovidedclinical

## 2.4.5. Conclusions on clinical pharmacology

The new proposed pharmaceutical form, film-coated dosage tablet forXtandi is considered comparable to the current capsule.

## 2.5. Clinical safety

Resultsfrom5biopharmaceuticalstudieswithvariousdevelopmenttablets(TabletsA,B,C,EandF)andthe to-be-marketedtabletwerepresented.Ofthese5studies,4weresingle-dosestudiesinvolvingatotalof219 0003).

<div style=\"page-break-after: always\"></div>

There were no deaths reported in any of the 5 biopharmaceutical studies.In addition, no subject discontinued anyofthe5biopharmaceuticalstudiesduetoanAE.

There were noobservable differences between the AEprofiles, laboratory,vital signs orECG databetween 0003),thesafetydataforthetabletwereconsistentwiththeknownsafetyprofileoftheenzalutamide capsuleinitsmarketedindication.

conditions and compared Tablet A and the capsule dosed to steady state.Across both treatment groups, a total of 24 (88.9%) patients experienced at least 1 TEAE including all 13 subjects in the capsule group and 11 1   s () h   s   s () t

The majority of patients (16 [59.3%]) experienced at least 1 grade 1 TEAE, 6 (22.2%) patients experienced TEAE. The distribution of TEAEs by grade was comparable between the 2 treatment groups. Grade 1 experienced at least 1 grade 2 TEAE compared to no grade 2 treatment-related TEAEs in the Tablet A group.

The SOCs with the most reported TEAEs across both treatment groups were Gastrointestinal disorders (11 [40.7%] patients), Investigations (9 [33.3%] patients), General disorders and administration site conditions

Diarrhoea (6 [22.2%] patients) was the most frequently reported TEAE. Overall, observed TEAEs were comparable for the 2 formulations,with a difference of no more than 1 to 2 patients at the PT level.

## 2.5.1. Discussion on clinical safety

studies in healthy volunteers were limited to small study durations in small groups of subjects(data not limited by the small number of patients treated with the tablet formulation (n = 14), while the combined

The overall safety profile of the enzalutamide tabletwas comparable to the safety profile of the capsule in the combined controlled population. No clinically significant differences in safety were observed for the tablet compared withthe capsuleinthemulti-dose study,9785-CL-0003，whichenrolledpatients withprostate cancer. No formulation-specific safety concerns were identified in the biopharmaceutical studies comparing the development Tablets A, B, C, E, and F, or the to-be-marketed tablet to the capsule.

## 2.5.2. Conclusions on the clinical safety

The new pharmaceutical form and strength are acceptable from safetyperspective.The current SmPC and RMPareadequatetoaddresstherisksofenzalutamidetablets.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk Management Plan

## Safety concerns

## SummaryofSafetyConcerns

| Important Identified Risks   | Seizure Posteriorreversibleencephalopathysyndrome(PRES) Hypertension Fall Neutrophil countdecreased Non-pathological fracture Cognitive/memoryimpairment InteractionswithstronginhibitorsorinducersofCYP2C8 InteractionswithmedicinalproductsthataresubstratesofCYP3A4,CYP2C9or CYP2C19   |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks    | None                                                                                                                                                                                                                                                                                      |
| Missing Information          | Patientswithsevererenalimpairment Reproduction/fertility Patients of non-white racet PatientswithECOGPS≥2 Patientswithseverecardiovasculardisease                                                                                                                                         |

## Pharmacovigilanceplan

Not applicable.

## Riskminimisationmeasures

| Safety Concern   | RoutineRiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Additional Risk Minimisation Measures   |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Seizure          | SmPCSection 4.4(Special warnings andprecautionsforuse)includes: Riskofseizure CautionshouldbeusedinadministeringXTANDItopatientswithahistoryof seizuresorotherpredisposingfactorsincluding,butnotlimitedto, underlyingbraininjury,stroke，primarybraintumoursorbrainmetastases， oralcoholism.Inaddition，theriskofseizuremaybeincreasedinpatients receivingconcomitantmedicinalproductsthatlowertheseizurethreshold. Thedecisiontocontinuetreatmentinpatientswhodevelopseizureshould be taken caseby case. SmPCSection 4.7(Effects on ability to driveandusemachines)includes: Enzalutamidemayhaveamoderateinfluenceontheabilitytodriveanduse machinesaspsychiatricandneurologiceventsincludingseizurehavebeen reported(seeSmPCsection4.8).Patientswithahistoryofseizuresorother predisposingfactors(seeSmPCsection4.4)shouldbeadvisedoftheriskof drivingoroperatingmachines.Nostudiestoestablishtheeffectsof enzalutamideontheabilitytodriveandusemachineshavebeen conducted. | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                     | Routine RiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Additional Risk Minimisation Measures   |
|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Seizure (continued)                                                                                | SmPCSection 4.8(Undesirable effects): Listed as undesirable effect. Descriptionofselectedadversereactions Seizure Incontrolledclinicalstudies,10patients(0.5%)experiencedaseizureout of2051patientstreatedwithadailydoseof160mgenzalutamide,whereas onepatient(<0.1%)receivingplaceboandonepatient(0.3%)receiving bicalutamide,experiencedaseizure.Doseappearstobeanimportant predictoroftheriskofseizure，asreflectedbypreclinicaldata，anddata fromadose-escalationstudy.Inthecontrolledclinicalstudies,patientswith priorseizureorriskfactorsforseizurewereexcluded. IntheAFFIRMtrial,sevenpatients(0.9%)experiencedaseizureoutof 800post-chemotherapypatientstreatedwithadailydoseof160mg enzalutamide,whereasnoseizuresoccurredinpatientsreceivingplacebo. thatmayhaveindependentlyincreasedtheirriskofseizure.InthePREVAIL trial,onepatient(0.1%)outof871chemotherapy-naivepatientstreated withadailydoseof160mgenzalutamide,andonepatient(0.1%)receiving placeboexperiencedaseizure. Inbicalutamide-controlledtrials,3patients(0.8%)out of380chemotherapy-naivepatientstreatedwithenzalutamideand1 patient(0.3%)outof387receivingbicalutamideexperiencedaseizure. Inasingle-armtrialtoassessincidenceofseizureinpatientswith predisposingfactorsforseizure(whereof1.6%hadahistoryofseizures,8 of366(2.2%)patientstreatedwithenzalutamideexperiencedaseizure. Themediandurationoftreatmentwas9.3months. Themechanismbywhichenzalutamidemaylowertheseizurethresholdis notknown,butcouldberelatedtodatafrominvitrostudiesshowingthat enzalutamideanditsactivemetabolitebindtoandcaninhibittheactivityof theGABA-gatedchloridechannel. SmPCSection 4.9(Overdose)includes: |                                         |
| Posteriorreversible encephalo-pathy syndrome (PRES)                                                | Patientsmaybeatincreasedriskofseizuresfollowinganoverdose. SmPCSection4.4(Specialwarningsandprecautionsforuse)includes: Posteriorreversibleencephalopathysyndrome Therehavebeenrarereportsofposteriorreversibleencephalopathy isarare，reversible,neurologicaldisorderwhichcanpresentwithrapidly evolvingsymptomsincludingseizure，headache,confusion,blindness，and othervisualandneurologicaldisturbances,withorwithoutassociated hypertension.AdiagnosisofPRESrequiresconfirmationbybrainimaging, patientswhodevelopPRESisrecommended. SmPCSection4.8(Undesirableeffects): Listed as undesirable effect.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | None                                    |
| Hypertension Fall Cognitive/memory impairment Neutrophil count decreased Non-pathological fracture | SmPCSection4.8(Undesirableeffects): Listedasundesirableeffects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | None                                    |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | AdditionalRisk Minimisation Measures   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Interactions with stronginhibitorsor inducersofCYP2C8 Interactions with medicinal products thatare substrates ofCYP3A4,CYP2C9 or CYP2C19 Interactions with stronginhibitorsor inducersofCYP2c8 Interactions with medicinalproducts thatare substrates 0fCYP3A4,CYP2C9 or CYP2C19 (continued) Interactions with stronginhibitorsor inducersofCYP2C8 Interactions with medicinalproducts that are substrates ofCYP3A4,CYP2C9 or CYP2C19 (continued) | Routine Risk Minimisation Measures SmPCSection4.2(Posologyandmethodofadministration)includes: ConcomitantusewithstrongCYP2C8inhibitors TheconcomitantuseofstrongCYP2C8inhibitorsshouldbeavoidedif possible.Ifpatientsmustbeco-administeredastrongCYP2c8inhibitor, thedoseofenzalutamideshouldbereducedto80mgoncedaily.If co-administrationofthestrongCYP2C8inhibitorisdiscontinued，the enzalutamidedoseshouldbereturnedtothedoseusedpriortoinitiationof thestrongCYP2C8inhibitor(seeSmPCsection4.5). SmPCSection 4.4(Special warnings andprecautionsforuse) includes: Concomitantusewithothermedicinalproducts manycommonlyusedmedicinalproducts(seeexamplesinSmPCsection 4.5).Areviewofconcomitantmedicinalproductsshouldthereforebe conductedwheninitiatingenzalutamidetreatment.Concomitantuseof enzalutamidewithmedicinalproductsthataresensitivesubstratesofmany metabolisingenzymesortransporters(seeSmPCsection4.5)should generallybeavoidediftheirtherapeuticeffectisoflargeimportancetothe patient,andifdoseadjustmentscannoteasilybeperformedbasedon monitoringofefficacyorplasmaconcentrations. Co-administrationwithwarfarinandcoumarin-likeanticoagulantsshouldbe avoided.IfXTANDIisco-administeredwithananticoagulantmetabolisedby CYP2c9(suchaswarfarinoracenocoumarol),additionalInternational NormalisedRatio(INR)monitoringshouldbeconducted(seeSmPC section 4.5). SmPCSection4.5(Interactionwithothermedicinalproductsandother formsofinteraction)includes: Potentialforothermedicinalproductstoaffectenzalutamideexposures CYP2C8inhibitors CYP2c8playsanimportantroleintheeliminationofenzalutamideandin theformationofitsactivemetabolite.Followingoraladministrationofthe strongCYP2C8inhibitorgemfibrozil(600mgtwicedaily)tohealthymale subjects,theAUCofenzalutamideincreasedby326%whileCmaxof enzalutamidedecreasedby18%.Forthesumofunboundenzalutamide plus theunbound activemetabolite,theAUCincreasedby77%whileCmax decreasedby19%.Stronginhibitors(e.g.gemfibrozil)ofCYP2c8aretobe avoidedorusedwithcautionduringenzalutamidetreatment.Ifpatients mustbeco-administeredastrongCYP2c8inhibitor,thedoseof enzalutamideshouldbereducedto80mgoncedaily(seeSmPCsection 4.2). CYP3A4inhibitors CYP3A4playsaminorroleinthemetabolismofenzalutamide.Following oraladministrationofthestrongCYP3A4inhibitoritraconazole(200mg oncedaily)tohealthymalesubjects,theAuCofenzalutamideincreasedby 41%whileCmaxwasunchanged.Forthesumofunboundenzalutamideplus theunboundactivemetabolite,theAUCincreasedby27%whileCmaxwas againunchanged.NodoseadjustmentisnecessarywhenXTANDris co-administeredwithinhibitorsofCYP3A4. CYP2C8andCYP3A4inducers FollowingoraladministrationofthemoderateCYP2C8andstrongCYP3A4 enzalutamideplustheactivemetabolitedecreasedby37%whileCmax remainedunchanged.NodoseadjustmentisnecessarywhenXTANDIisco- administeredwithinducersofCYP2C8orCYP3A4. | None                                   |

<div style=\"page-break-after: always\"></div>

| SafetyConcern                                                                                                                                        | RoutineRiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Additional Risk Minimisation Measures   |
|------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Interactions with stronginhibitorsor inducersofCYP2c8 Interactions with medicinal products thatare substrates OfCYP3A4,CYP2C9 or CYP2C19 (continued) | Potentialforenzalutamidetoaffectexposurestoothermedicinalproducts Enzymeinduction Enzalutamideisapotentenzymeinducerandincreasesthesynthesisof manyenzymesandtransporters;therefore,interactionwithmanycommon medicinalproductsthataresubstratesofenzymesortransportersis expected.Thereductioninplasmaconcentrationscanbesubstantial,and leadtolostorreducedclinicaleffect.Thereisalsoariskofincreased formationofactivemetabolites.Enzymesthatmaybeinducedinclude CYP3Aintheliverandgut,CYP2B6,CYP2C9,CYP2C19,anduridine5'- othertransportersaswell,e.g.multidrugresistance-associatedprotein2 transportingpolypeptide1B1(OATP1B1). InvivostudieshaveshownthatenzalutamideisastronginducerofCYP3A4 andamoderateinducerofCYP2C9andCYP2C19.Co-administrationof enzalutamide(160mgoncedaily)withsingleoraldosesofsensitiveCYP substratesinprostatecancerpatientsresultedinan86%decreaseinthe AUCofmidazolam(CYP3A4substrate),a56%decreaseintheAUCofS- warfarin(CYP2C9substrate),anda70%decreaseintheAUCof omeprazole(CYP2C19substrate).UGT1A1mayhavebeeninducedaswell. InaclinicalstudyinpatientswithmetastaticCRPC,XTANDI（160mgonce daily)hadnoclinicallyrelevanteffectonthepharmacokineticsof intravenouslyadministereddocetaxel(75mg/m²byinfusionevery3 weeks).TheAUCofdocetaxeldecreasedby12%[geometricmeanratio (GMR)=0.882(90%CI:0.767,1.02)】whileCmaxdecreasedby4%[GMR =0.963 (90% CI:0.834,1.11)]. Interactionswithcertainmedicinalproductsthatareeliminatedthrough metabolismoractivetransportareexpected.Iftheirtherapeuticeffectisof largeimportancetothepatient，anddoseadjustmentsarenoteasily medicinalproductsaretobeavoidedorusedwithcaution.Theriskforliver injuryafterparacetamoladministrationissuspectedtobehigherinpatients concomitantlytreatedwithenzymeinducers. |                                         |

<div style=\"page-break-after: always\"></div>

| SafetyConcern                                                                                                                                         | RoutineRiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Additional Risk Minimisation Measures   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Interactions with stronginhibitors or inducersofCYP2c8 Interactions with medicinal products thatare substrates ofCYP3A4,CYP2C9 or CYP2C19 (continued) | Groupsofmedicinalproductsthatcanbeaffectedinclude,butarenot limitedto: ·Analgesics(e.g.fentanyl,tramadol) Antibiotics（e.g.clarithromycin，doxycycline) Anticanceragents(e.g.cabazitaxel) Anticoagulants(e.g.acenocoumarol,warfarin) Antiepileptics(e.g.carbamazepine,clonazepam,phenytoin,primidone, valproicacid) Antipsychotics(e.g.haloperidol) Betablockers(e.g.bisoprolol,propranolol) Calciumchannel blockers(e.g.ditiazem,felodipine,nicardipine, nifedipine,verapamil) Cardiacglycosides(e.g.digoxin) Corticosteroids(e.g.dexamethasone,prednisolone) HIVantivirals(e.g.indinavir,ritonavir) Hypnotics（e.g.diazepam,midazolam,zolpidem) StatinsmetabolizedbyCYP3A4(e.g.atorvastatin,simvastatin) Thyroidagents(e.g.levothyroxine) Thefullinductionpotentialofenzalutamidemaynotoccuruntil approximately1monthafterthestartoftreatment,whensteady-state plasmaconcentrationsofenzalutamidearereached,althoughsome inductioneffectsmaybeapparentearlier.Patientstakingmedicinal productsthataresubstrateSofCYP2B6,CYP3A4，CYP2C9,CYP2C19,or UGT1A1shouldbeevaluatedforpossiblelossofpharmacologicaleffects(or increaseineffectsincaseswhereactivemetabolitesareformed)duringthe firstmonthofenzalutamidetreatment，anddoseadjustmentshouldbe consideredasappropriate.Inconsiderationofthelonghalf-lifeof enzalutamide(5.8days,seeSmPCsection5.2),effectsonenzymesmay persistforonemonthorlongerafterstoppingenzalutamide.Agradual dosereductionoftheconcomitantmedicinalproductmaybenecessary whenstoppingenzalutamidetreatment. | None                                    |
| Patients with severe renal impairment                                                                                                                 | SmPCSection4.2（Posologyandmethodofadministration)include: Renalimpairment impairment(seeSmPCsection5.2).Cautionisadvisedinpatientswith severerenalimpairmentorend-stagerenaldisease(seeSmPCsection 4.4). SmPCSection4.4(Specialwarningsandprecautionsforuse)includes: Renalimpairment Cautionisrequiredinpatientswithsevererenalimpairmentas enzalutamidehasnotbeenstudiedinthispatientpopulation. SmPCSection5.2(Pharmacokineticproperties)includes: Renalimpairment Noformalrenalimpairmentstudyforenzalutamidehasbeencompleted. Patientswithserumcreatinine>177μmol/L(2mg/dL)wereexcludedfrom clinicaltrials.Basedonapopulationpharmacokineticanalysis,nodose adjustmentisnecessaryforpatientswithcalculatedcreatinineclearance (CrCL)values≥30mL/min(estimatedbytheCockcroftandGaultformula). Enzalutamidehasnotbeenevaluatedinpatientswithsevererenal impairment(CrCL<30mL/min)orend-stagerenaldisease,andcautionis advisedwhentreatingthesepatients.Itisunlikelythatenzalutamidewillbe significantlyremovedbyintermittenthaemodialysisorcontinuous ambulatoryperitonealdialysis.                                                                                                                                                                                                                                                                                                                                                                                                                                              | None                                    |

<div style=\"page-break-after: always\"></div>

| SafetyConcern                           | RoutineRiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | AdditionalRisk Minimisation Measures   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Reproduction/ fertility                 | SmPCSection4.3(Contraindications)includes: Contraindicationsincludewomenwho are ormaybecomepregnant(see SmPCsection4.6). SmPCSection4.6(Fertility,pregnancy andlactation)includes: Womenofchildbearingpotential TherearenohumandataontheuseofXtandiinpregnancyandthis medicinalproductisnotforuseinwomenofchildbearingpotential.This medicinemaycauseharmtotheunbornchildorpotentiallossofpregnancy Contraceptioninmalesandfemales Itisnotknownwhetherenzalutamideoritsmetabolitesarepresentin semen.Acondomisrequiredduringandfor3monthsaftertreatmentwith enzalutamideifthepatientisengagedinsexualactivitywithapregnant woman.Ifthepatientengagesinsexualintercoursewithawomanof usedduringandfor3monthsaftertreatment.Studiesinanimalshave shownreproductivetoxicity(seeSmPCsection5.3). Pregnancy Enzalutamideisnotforuseinwomen.Enzalutamideiscontraindicatedin womenwhoareormaybecomepregnant(seeSmPCsections4.3and5.3). Breast-feeding Enzalutamideisnotforuseinwomen.Itisnotknownifenzalutamideis presentinhumanmilk.Enzalutamideand/oritsmetabolitesaresecretedin rat milk(see SmPC section 5.3). Fertility Animalstudiesshowedthatenzalutamideaffectedthereproductivesystem inmaleratsanddogs(seeSmPCsection5.3). | None                                   |
| Patients ofnon- white race              | SmPCSection5.1(Pharmacodynamicproperties)includes: Clinicalefficacyandsafety MDV31o0-03(PREVAIL)study(chemotherapy-naivepatients) Patientdemographicsandbaselinediseasecharacteristicswerebalanced betweenthetreatmentarms.Themedianagewas71years（range42-93) andtheracialdistributionwas77%Caucasian,10%Asian,2%Blackand 11%otherorunknownraces.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | None                                   |
| Patients of non- white race (continued) | CRPC2(AFFIRM) study(patientswho previouslyreceived chemotherapy) Thefollowingpatientdemographicsandbaselinediseasecharacteristics werebalancedbetweenthetreatmentarms.Themedianagewas69years (range41-92)andtheracialdistributionwas92.7%Caucasian,3.9% Black,1.1%Asian,and2.1%Other. SmPCSection5.2(Pharmacokineticproperties)includes: Race Mostpatientsintheclinicaltrials（>84%)wereCaucasian.Basedon pharmacokineticdatafromastudyinJapanesepatientswithprostate cancer,therewerenoclinicallyrelevantdifferencesinexposurebetween JapaneseandCaucasians.Thereareinsufficientdatatoevaluatepotential differencesinthepharmacokineticsofenzalutamideinotherraces._                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                        |

<div style=\"page-break-after: always\"></div>

| SafetyConcern                               | RoutineRiskMinimisationMeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Additional Risk Minimisation Measures   |
|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| PatientswithEcoG PS ≥ 2                     | SmPCSection5.1(Pharmacodynamicproperties)includes: Clinical efficacy and safety MDV3100-03(PREVAIL)study(chemotherapy-naivepatients) Sixty-eightpercent(68%)ofpatientshadanECoGperformancestatus scoreof0and32%patientshadEcoGperformancestatus1. CRPC2(AFFIRM) study(patients who previously received chemotherapy) TheECOGperformancescorewas0-1in91.5%ofpatientsand2in8.5% ofpatients.                                                                                                                                                                                               | None                                    |
| Patients with severe cardiovascular disease | SmPC Section 5.1 (Pharmacodynamic properties)includes: Clinicalefficacyandsafety MDV3100-03(PREVAIL)study(chemotherapy-naivepatients) heartfailure(NYHAClass1or2)...wereallowed. CRPC2(AFFIRM) study(patientswho previouslyreceived chemotherapy) TheAFFIRMstudyexcludedpatientswith..clinicallysignificant cardiovasculardiseasesuchasuncontrolledhypertension,recenthistoryof myocardialinfarctionorunstableangina,NewYorkHeartAssociationclass IIIorIVheartfailure(unlessejectionfractionwas≥45%),clinically significantventriculararrhythmiasorAVblock(withoutpermanent pacemaker). | None                                    |

## Conclusion

proposed by the MAH due to the addition of the new pharmaceutical form and strength.This is acceptable.

The CHMP and PRAC considered that the risk management plan version 12 is acceptable.

## 2.7.Pharmacovigilance

## Pharmacovigilancesystem

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirementsofArticle8(3)ofDirective2001/83/EC

## PeriodicSafetyUpdateReportssubmissionrequirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in thelistofUnionreferencedates(EURDlist)providedforunderArticle107c(7)ofDirective2001/83/ECand

<div style=\"page-break-after: always\"></div>

## 2.8.Productinformation

The product information has been updated to reflect the new pharmaceutical form and strengths.

andotherrelevantguideline(s)whichwerereviewedbyQRDandacceptedbytheCHMP.

## 2.8.1. User consultation

showthatthepackageleafletmeetsthecriteriaforreadabilityassetoutintheGuidelineonthereadability ofthelabelandpackageleafletofmedicinalproductsforhumanuse.

## 3. Benefit-Risk Balance

## 3.1.TherapeuticContext

currentlyapprovedindications:

- the treatment of adult men with metastatic castration-resistant prostate cancer (CPRC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapyisnotyetclinicallyindicated(seesection5.1)
- the treatment of adult men with metastatic castration-resistant prostate cancer (CPRC) whose disease has progressed on or after docetaxel therapy.

Theapplicationisbasedontheresultsofapivotalclinicalstudyevaluatingthebioequivalencebetween enzalutamidecapsulesandtabletsforsingle-doseAUCunderfastedandfedconditions(Study9785-CLorder to assess Cmax under conditions of clinical use, and an exposure-response analysis to evaluate the

## 3.2.Favourableeffects

Thebioequivalence of test andreference product(capsules)was demonstrated for 80 mg strengthinboth Advice, a PK simulation to steady stated, using non-parametric superposition model was submitted and showedthatCmaxdifferencesaftersingle-dosearenotclinicalrelevant.Thisisfurthersupportedbyan section 4.1.6of thebioequivalence guideline arefulfilled.

Therefore, the same favourable effects as shown forXtandi capsule can be concluded for Xtandi film-coated tablets (40 mg and 80 mg).

<div style=\"page-break-after: always\"></div>

## 3.3.Uncertaintiesandlimitationsaboutfavourableeffects

Not applicable.

## 3.4. Unfavourable effects

The overallsafetyprofileof the enzalutamide tabletwas comparable to the safetyprofileofthecapsule.No tablet compared with the capsule.

## 3.5.Uncertaintiesandlimitationsaboutunfavourableeffects

Not applicable.

## 3.6.EffectsTable

Not applicable.

## 3.7.Benefit-riskassessmentanddiscussion

## 3.7.1.Importance of favourable and unfavourable effects

Based on the data provided,the efficacy and safety of the currently approved liquid-filled, soft gelatine coatedtabletsand80mgfilmcoatedtablets).

## 3.7.2. Balance of benefits and risks

Thebenefits ofXtandi 40mg film coated tablets and 80mgfilm-coated tabletsoutweigh therisks.The productinformationincludesrelevantsafetyinformation and theRMPis adequate tomanage therisks of the product.

## 3.8.Conclusions

TheoverallbenefitriskbalanceofXtandi ispositive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Xtandi 40 mg and 80 mg film-coated tables is favourable in the following indication:

<div style=\"page-break-after: always\"></div>

- thetreatmentofadultmenwithmetastaticcastration-resistantprostatecancer(CPRC)whoare chemotherapy isnotyetclinicallyindicated(seesection5.1)
- the treatment of adult men with metastatic castration-resistant prostate cancer(CPRC) whose disease has progressed on or after docetaxel therapy.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Xtandi subject to the following conditions:

## Conditions orrestrictionsregarding supply anduse

Medicinal product subject to medical prescription

## Conditionsandrequirementsofthemarketingauthorisation

## PeriodicSafetyUpdateReports

Therequirementsfor submission of periodic safety update reports for this medicinal product are set out in anysubsequentupdatespublishedon theEuropeanmedicinesweb-portal.

## Conditionsorrestrictionswithregard tothesafeandeffectiveuseofthe medicinalproduct

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP.

AnupdatedRMPshouldbesubmitted:

- ·At the request of the European Medicines Agency;
- beingreceivedthatmayleadtoasignificantchangetothebenefit/riskprofileorastheresultofan